£490.00

The 2023-2028 Outlook for Chronic Obstructive Pulmonary Disease Treatments for US Zip Codes

Subjects

Price data checked 6 days ago

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£490 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 85 days · 85 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 85 days • 1 price levels

Days at Price

Price Analysis

Most common price: £490 (85 days, 100.0%)

Price range: £490 - £490

Price levels: 1 different prices over 85 days

Description

This study covers the latent demand outlook for chronic obstructive pulmonary disease treatments across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each zip code in question, the percent share the zip code is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a zip code vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and zip code, latent demand estimates are created for chronic obstructive pulmonary disease treatments. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of chronic obstructive pulmonary disease treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Mylan NV, Novartis International, Orion, Sunovion Pharmaceuticals, and Teva Pharmaceutical Industries. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).

Product Specifications

Format: paperback
ASIN: B0BSJC38RN
Category: Books > Subjects
Domain: Amazon UK
Release Date: 09 January 2023
Listed Since: 27 January 2023

The 2023-2028 Outlook for Chronic Obstructive Pulmonary Disease Treatments for US Zip Codes

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2023-2028 Outlook for Idiopathic Pulmonary Fibrosis Treatments for US Zip Codes

The 2013-2018 Outlook for Chronic Obstructive Pulmonary Disease (COPD) Therapeutics in India

The 2023-2028 Outlook for Pulmonary Fibrosis Treatments for US Zip Codes

The 2023-2028 Outlook for Respiratory Disorder Treatments for US Zip Codes

The 2023-2028 Outlook for Idiopathic Pulmonary Fibrosis Treatments in China

The 2023-2028 Outlook for Idiopathic Pulmonary Fibrosis Treatments in Japan

The 2016-2021 World Outlook for Chronic Obstructive Pulmonary Disease (COPD) Therapeutics

The 2023-2028 Outlook for Idiopathic Pulmonary Fibrosis Treatments in India

The 2023-2028 World Outlook for Idiopathic Pulmonary Fibrosis Treatments

The 2023-2028 Outlook for Pulmonary Fibrosis Treatments in China

The 2023-2028 World Outlook for Idiopathic Pulmonary Fibrosis

The 2025-2030 World Outlook for Idiopathic Pulmonary Fibrosis Treatments

The 2023-2028 Outlook for Non-Small Cell Lung Cancers for US Zip Codes

The 2023-2028 Outlook for Pulmonary Fibrosis Treatments in Japan

The 2025-2030 World Outlook for Idiopathic Pulmonary Fibrosis

The 2023-2028 Outlook for Respiratory Disorder Treatments in China

The 2023-2028 Outlook for Pulmonary Fibrosis Treatments in the United States

Chronic Obstructive Pulmonary Disease - Contemporary and Consummate Management of a Systemic Disorder

IntechOpen Chronic Obstructive Pulmonary Disease Book

The 2023-2028 Outlook for Respiratory Disorder Treatments in Japan

The 2023-2028 World Outlook for Pulmonary Fibrosis Treatments

The 2023-2028 Outlook for Pulmonary Fibrosis Treatments in India

The 2023-2028 Outlook for Asthma Treatments for US Zip Codes

Chronic Obstructive Pulmonary Disease: A Current Conspectus